13F reference period
n/a
Security Snapshot
ABEONA THERAPEUTICS INC - COM (ABEO) Institutional Ownership
CUSIP: 00289Y107
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2025
Institutions Reporting
Shares (Excl. Options)
Price
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COM
- Symbol
- ABEO on Nasdaq
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ABEO - ABEONA THERAPEUTICS INC - COM is tracked under CUSIP 00289Y107.
- 13F reference-period holder data is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder data for the Q2 2026 reference period is not available.
- Available periods remain in the history table; they do not substitute for the headline period.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
00289Y107
13F reference period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
ABEO full holder history
ABEONA THERAPEUTICS INC. SEC filings
ABEONA THERAPEUTICS INC. company facts
ABEONA THERAPEUTICS INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00289Y107:
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
33
Headline period
n/a
Rows shown
1-25 of 33
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q1 | 0 | $0 | -$13,066 | 0 | |
| 2024 Q4 | 2,350 | $13,066 | +$13,066 | $5.56 | 1 |
| 2022 Q4 | 0 | $0 | -$281,000 | 0 | |
| 2022 Q3 | 153,702 | $281,000 | -$10,316,109 | $1.61 | 2 |
| 2022 Q2 | 20,873,758 | $4,338,025 | -$3,565,661 | $0.21 | 35 |
| 2022 Q1 | 32,609,380 | $10,277,038 | -$2,038,846 | $0.31 | 46 |
| 2021 Q4 | 40,902,465 | $13,669,979 | +$3,297,234 | $0.34 | 45 |
| 2021 Q3 | 25,219,481 | $28,251,178 | -$3,241,034 | $1.12 | 51 |
| 2021 Q2 | 27,815,873 | $43,416,187 | -$5,850,446 | $1.56 | 65 |
| 2021 Q1 | 31,075,128 | $58,418,929 | -$1,878,954 | $1.88 | 69 |
| 2020 Q4 | 32,419,497 | $50,901,641 | -$1,664,634 | $1.57 | 69 |
| 2020 Q3 | 35,924,992 | $36,686,570 | -$14,321,084 | $1.02 | 73 |
| 2020 Q2 | 43,438,319 | $126,435,760 | -$1,417,436 | $2.92 | 77 |
| 2020 Q1 | 44,494,860 | $93,349,190 | -$36,312,820 | $2.10 | 78 |
| 2019 Q4 | 55,008,923 | $179,886,101 | +$80,967,799 | $3.27 | 85 |
| 2019 Q3 | 28,565,456 | $64,562,551 | -$3,332,761 | $2.26 | 77 |
| 2019 Q2 | 28,969,765 | $138,472,723 | -$19,625,407 | $4.78 | 93 |
| 2019 Q1 | 31,271,523 | $230,147,728 | -$9,348,459 | $7.36 | 83 |
| 2018 Q4 | 32,565,185 | $232,447,763 | -$24,647,383 | $7.14 | 97 |
| 2018 Q3 | 34,766,258 | $444,445,898 | -$24,732,558 | $12.80 | 104 |
| 2018 Q2 | 36,551,563 | $584,822,416 | +$61,355,864 | $16.00 | 92 |
| 2018 Q1 | 32,800,697 | $470,553,406 | +$46,998,758 | $14.35 | 88 |
| 2017 Q4 | 29,294,827 | $464,314,681 | +$152,009,642 | $15.85 | 93 |
| 2017 Q3 | 19,617,144 | $334,470,272 | +$83,896,681 | $17.05 | 73 |
| 2017 Q2 | 15,387,716 | $98,477,237 | +$8,202,570 | $6.40 | 64 |